Cargando…

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

INTRODUCTION: Response to current therapy of hepatitis C virus (HCV) is suboptimal. Direct-acting antiviral therapies (DAA) are expected to improve treatment outcomes. Additional treatments for HCV will invariably make therapeutic choices and patient management more complex. We hypothesize that curr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaglio, Paul J., Moss, Noah, McGaw, Camille, Reinus, John
Formato:	Texto
Lenguaje:	English
Publicado:	Springer US 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082020/ https://www.ncbi.nlm.nih.gov/pubmed/21336604 http://dx.doi.org/10.1007/s10620-011-1604-3

Ejemplares similares

Ineffective Absorption? Failure of Direct-Acting Therapy for Chronic Hepatitis C in Cirrhotic Patients With Roux-en-Y Gastric Bypass
por: Tow, Clara Y., et al.
Publicado: (2019)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
por: Chae, Hee Bok, et al.
Publicado: (2013)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2020)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Hepatitis C Virus-associated Membranoproliferative Glomerulonephritis Treated with Directly Acting Antiviral Therapy
por: Nayak, S., et al.
Publicado: (2018)

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
por: Sato, Ken, et al.
Publicado: (2022)

Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection
por: Matsumoto, Kotaro, et al.
Publicado: (2018)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014)

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C
por: Yamazaki, Tomoo, et al.
Publicado: (2018)

Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
por: Westermann, Claudia, et al.
Publicado: (2018)

Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy
por: Fierer, Daniel S, et al.
Publicado: (2020)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Safety and efficacy of directly‐acting antiviral therapy for chronic hepatitis C virus in elderly people
por: De Santis, Adriano, et al.
Publicado: (2021)

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
por: Cartwright, Emily J., et al.
Publicado: (2023)

Knowledge and Attitude Related to Hepatitis C among Medical Students in the Oral Direct Acting Antiviral Agents Era in Vietnam
por: Pham, Thi Thanh Hang, et al.
Publicado: (2022)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Liver cT(1) decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus
por: Jayaswal, Arjun N. A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rhbbthrjs3bp2ma2693sgnn9b5